BioCentury
ARTICLE | Politics, Policy & Law

Novartis’ Narasimhan calls for value-based pricing--and access

Novartis CEO Vas Narasimhan’s views on pricing, value and price-control legislation

December 13, 2019 8:59 PM UTC
Updated on Dec 13, 2019 at 9:24 PM UTC

Novartis CEO Vas Narasimhan believes drug prices and access should be based on value. He’s in favor of the use of cost-effectiveness assessments to justify drug prices -- which creates winners and losers -- and is staking his ground in confidence that Novartis can produce best-in-class medicines that would be rewarded.

BioCentury sat down with Narasimhan for a broad-ranging discussion on the state of biopharma and his outlook. In the first of a three-part series from that conversation, the biopharma executive shares his perspectives on drug pricing and other policy issues. Over the coming weeks, BioCentury will publish his comments on innovation, reimbursement and his company strategy...

BCIQ Company Profiles

Novartis AG